This partnership is part of a new era in ingredients targeted for infant nutrition.
ST. LOUIS, Mo. (PRWEB) November 03, 2016
Today DuPont Nutrition & Health (DuPont) announced a joint development and licensing agreement for exclusive rights to selected fucosylated human milk oligosaccharides (HMOs), including 2’-fucosyllactose, with Inbiose, a Belgium-based producer of specialty carbohydrates.
“This partnership is part of a new era in ingredients targeted for infant nutrition,” said John Rea, global business unit leader for Probiotics, Cultures, Food Protection and HMOs. “With this development, we’re working toward fulfilling our corporate mission to help solve the world’s food challenges by providing innovative ingredients our customers can use to make healthy and nutritious products. Our investment here complements the broad capabilities DuPont has built in probiotics and understanding the human gut microbiome, as well as our technologies already targeting this area.”
HMOs are a group of unique oligosaccharides found in mother’s milk, with 2’-fucosyllactose being the single most abundant HMO. This new partnership combines Inbiose’s innovative production platform for specialty carbohydrates with DuPont’s capabilities in industrial-scale fermentation, regulatory and health science expertise, as well as global market access.
The partnership is currently focusing on developing the ingredients for market introduction by implementing an industrial-scale fermentation process and submission for regulatory approvals to enter the market in 2017. “We are excited to collaborate with Inbiose and bring the science of HMOs to market,” said Martin Kullen, global R&D leader for Probiotics, Cultures, Food Protection and HMOs. “HMOs are key in helping our customers move another step closer to matching the composition of human milk with their infant nutrition products.”
HMOs have been identified as important components of human milk that help shape an infant’s gut microbiome and a balanced immune system development. A growing body of evidence suggests that HMOs benefit the health of developing infants by supporting digestive, immune and cognitive development(1).
“Our collaboration with DuPont, a world-renown ingredient manufacturer, advances our technology and will accelerate the introduction of our first HMO to improve the health and well-being of infants,” said Prof. Wim Soetaert, executive chairman of Inbiose.
Digestive/gut health was the primary claim associated with infant formula launches in 2015, according to market research firm Innova(2). It was featured on 58 percent of all launches in the market. Over the past five years, the use of prebiotics in infant formulas has dramatically increased.
“HMOs are found naturally in mother’s milk and represent the next generation of functional oligosaccharides. The inclusion of HMOs will be a significant advancement in the improvement of infant formula,” said Kullen. “With our experience delivering products to the strict safety and efficacy standards required for the infant formula segment, DuPont will be at the forefront of commercializing HMOs.”
Inbiose is a Belgium-based company that has developed a proprietary production platform for the industrial production of specialty carbohydrates. HMOs are important targets for Inbiose and the market launch of 2’-fucosyllactose represents a key milestone for the company. Inbiose is currently developing new processes for other HMOs and specialty carbohydrates. For additional information about Inbiose, please visit http://www.inbiose.com.
DuPont Nutrition & Health combines in-depth knowledge of food and nutrition with current research and expert science to deliver unmatched value to the food, beverage and dietary supplement industries. We are innovative solvers, drawing on deep consumer insights and a broad product portfolio to help our customers turn challenges into high-value business opportunities. More information is available at http://www.food.dupont.com.
DuPont (NYSE: DD) has been bringing world-class science and engineering to the global marketplace in the form of innovative products, materials, and services since 1802. The company believes that by collaborating with customers, governments, NGOs, and thought leaders we can help find solutions to such global challenges as providing enough healthy food for people everywhere, decreasing dependence on fossil fuels, and protecting life and the environment. For additional information about DuPont and its commitment to inclusive innovation, please visit http://www.dupont.com.
# # #
11/03/16
Foot Notes
(1) Bode, L. (2015). The functional biology of human milk oligosaccharides. Early Human Development, 91, first 619-622.
(2) Formulation Trends in Baby Formula/Milk”, March 2016, Innova Market Insights.